Onpattro
E446845
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Onpattro canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T4492413 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Onpattro Context triple: [Alnylam Pharmaceuticals, develops, Onpattro]
-
A.
Inflectra
Inflectra is a biosimilar monoclonal antibody to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
-
B.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
-
C.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
D.
Imbruvica
Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
-
E.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Onpattro Target entity description: Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
-
A.
Inflectra
Inflectra is a biosimilar monoclonal antibody to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
-
B.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
-
C.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
D.
Imbruvica
Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
-
E.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
- F. None of above. chosen
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
RNA interference therapeutic
ⓘ
drug ⓘ orphan drug ⓘ prescription medicine ⓘ small interfering RNA ⓘ |
| actsOn | transthyretin mRNA ⓘ |
| approvedBy |
European Medicines Agency
NERFINISHED
ⓘ
U.S. Food and Drug Administration NERFINISHED ⓘ |
| commonAdverseEffect |
back pain
ⓘ
fatigue ⓘ flushing ⓘ headache ⓘ infusion-related reaction ⓘ nausea ⓘ |
| containsExcipient |
DLin-MC3-DMA
ⓘ
PEGylated lipid ⓘ cholesterol ⓘ lipid excipients ⓘ |
| countryOfFirstApproval | United States of America NERFINISHED ⓘ |
| developedBy | Alnylam Pharmaceuticals NERFINISHED ⓘ |
| dosageForm | concentrate for solution for infusion ⓘ |
| dosingInterval | once every three weeks ⓘ |
| hasActiveIngredient | patisiran NERFINISHED ⓘ |
| hasApprovalYear | 2018 ⓘ |
| hasATCCode | N07XX13 ⓘ |
| hasDrugClass |
gene-silencing therapy
ⓘ
transthyretin expression inhibitor ⓘ |
| hasIndication | polyneuropathy in adults with hereditary transthyretin-mediated amyloidosis ⓘ |
| hasInternationalNonproprietaryName | patisiran NERFINISHED ⓘ |
| hasLegalStatus | prescription only ⓘ |
| hasPregnancyCategory | not recommended during pregnancy unless clearly needed ⓘ |
| hasTherapeuticArea |
neurology
ⓘ
rare diseases ⓘ |
| improves | neuropathy impairment scores in hATTR patients ⓘ |
| isAdministeredBy | healthcare professional ⓘ |
| isFormulatedAs | lipid nanoparticle ⓘ |
| marketingAuthorizationHolder | Alnylam Pharmaceuticals NERFINISHED ⓘ |
| mayCause | vitamin A deficiency ⓘ |
| mechanismOfAction |
RNA interference
ⓘ
silencing of transthyretin gene expression in the liver ⓘ |
| reduces | serum transthyretin levels ⓘ |
| reducesLevelOf | transthyretin protein ⓘ |
| requires | premedication to reduce infusion-related reactions ⓘ |
| requiresMonitoringOf | vitamin A levels ⓘ |
| requiresSupplementationOf | vitamin A ⓘ |
| routeOfAdministration | intravenous infusion ⓘ |
| targetOrgan | liver ⓘ |
| treats |
hATTR amyloidosis with polyneuropathy
ⓘ
hereditary transthyretin-mediated amyloidosis ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Onpattro Description of subject: Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.